Type 2 diabetes

New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function. The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with placebo. The results were presented […]

Individuals with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease, a large epidemiological study has revealed.  The research – led by KU Leuven in collaboration with colleagues in the UK, including the University of Glasgow, and published in The Lancet – shows for the first time that cardiovascular risks affect autoimmune […]

Lowering high blood pressure is an effective way to reduce a person’s risk of developing Type 2 diabetes in the future, according to research funded by the British Heart Foundation (BHF) and published in The Lancet.  Doctors already prescribe blood pressure-lowering drugs to reduce a person’s chance of having a life-threatening heart attack or stroke, but […]

Glyscend has presented data during the American Diabetes Association 80th Scientific Sessions virtual meeting, from a study of its proprietary oral polymer duodenal exclusion therapy. The positive data were presented ahead of Glyscend’s Phase I clinical trials, which have commenced recruiting healthy subjects in South Australia. Glyscend is developing a new class of oral gut-restricted […]

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide has the potential to achieve […]

Research published in Nature Communications by a team from Lund University in Sweden has discovered that in Type 2 diabetes, a specific gene influences muscle stem cells’ ability to create new mature muscle cells. “In people with Type 2 diabetes, the VPS39 gene is significantly less active in the muscle cells than it is in […]

According to new research, two new but commonly-used diabetes drugs, one of which is also now approved for use in heart failure in people with or without diabetes, might be more effective in people with an Asian background than in people with a White background.    The study, led by the University of Glasgow, found […]